Navigation Links
Targanta in Medical Technology

Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria

... CHICAGO, Sept. 19 /PRNewswire/ -- targanta Therapeutics Corporation today released detailed d...s (cSSSI) in which the primary endpoints were met. targanta believes oritavancin's properties may give it dist...ize oritavancin for the treatment of cSSSI. About targanta Therapeutics ...

Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models

...overy Platform CHICAGO, Sept. 19 /PRNewswire/ -- targanta Therapeutics Corporation today released detailed d...tration (FDA) as a significant unmet medical need. targanta has developed a novel drug discovery platform thro...nt as a possible therapy for osteomyelitis. About targanta Therapeutics ...

Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria

... Vitro Methods CHICAGO, Sept. 19 /PRNewswire/ -- targanta Therapeutics Corporation today released data from ...lls (5- to 13-fold lower MICs against the spores); targanta believes that such a phenomenon has not been repor...s (cSSSI) in which the primary endpoints were met. targanta believes oritavancin's properties may give it dist...

Targanta Initiates Phase 2 Oritavancin Infrequent Dosing Study

...cSSSI CAMBRIDGE, Mass., Sept. 13 /PRNewswire/ -- targanta Therapeutics Corporation today announced the initi...amine safety data in all intent-to-treat patients. targanta expects to enroll a total of 300 patients in this ...n (cSSSI) in which the primary endpoints were met. targanta believes oritavancin's properties may give it dist...

Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics

...said Thomas Parr, Ph.D., Chief Scientific Officer, targanta Therapeutics. "These data further support oritavan...al treatment for serious bacterial infections, and targanta will continue to explore this potential through on...med by former developers Lilly and InterMune, Inc. targanta expects to file a New Drug Application (NDA) for o...

Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax

...val rate at 30 days. Researchers at USAMRIID and targanta concluded that their results provide impetus for i...velopers Eli Lilly and Company and InterMune, Inc. targanta expects to file a New Drug Application (NDA) for o...ministration in the first quarter of 2008. About targanta Therapeutics Corporation ...
Targanta in Biological Technology

InterMune Reports First Quarter 2009 Financial Results and Business Highlights

...ly $6.0 million received in the first quarter of 2009 from the acquisition by The Medicines Company of InterMune's approximately 3.0 million shares of targanta Therapeutics Corporation. On January 1, 2009, the company adopted Financial Accounting Standards Board Staff Position APB 14-1, "Accounting fo...

InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights

... completed its tender offer for all of the outstanding shares of targanta Therapeutics Corporation. Based on InterMune's ownership of approximately 3 million targanta shares, InterMune expects to receive approximately $6.0 million in t...

Targanta Submits Oritavancin New Drug Application

...lizations, and increased healthcare costs. About targanta Therapeutics targanta Therapeutics Corporation is a biopharmaceutical co...d Montreal, Quebec, Canada. To find out more about targanta Therapeutics Corp. (Nasdaq: TARG ), visit our web...

InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance

...lion, compared with $214.5 million at December 31, 2006. In October 2007, targanta Therapeutics completed an initial public offering of its common stock, which resulted in the conversion of InterMune's interest in targanta into approximately 3.0 million shares of Targanta common stock. As of Decem...

Targanta to Present at Lazard Capital Markets Fourth Annual Healthcare Conference

...ite at http://www.targanta.com/investors . About targanta Therapeutics targanta Therapeutics Corporation is a biopharmaceutical co...i-synthetic lipoglycopeptide antibiotic, for which targanta intends to seek U.S. regulatory approval in early ...

Targanta to Present at 9th Annual Mass Opportunities Investment Conference

...ite at http://www.targanta.com/investors . About targanta Therapeutics targanta Therapeutics Corporation is a biopharmaceutical co...i-synthetic lipoglycopeptide antibiotic, for which targanta intends to seek U.S. regulatory approval in early ...

Biotech Continues Upward Climb in October

... offering at $12, 20% below the midpoint of their proposed $14 to $16 range. During the month its shares strengthened to close at $13.88. -- targanta Therapeutics, which developing an antibiotic treatment for gram-positive bacterial infections, priced 5.8 million shares at $10 per share, 30%...

2007 Massachusetts Biotechnology Council MASS Opportunities Investment Conference Showcases Leading Growth Companies

...ticals, Molecular, Biometrics, Molecular Insight Pharmaceuticals, Momenta Pharmaceuticals, Nitromed Inc., Oscient Pharmaceuticals, Primera Biosystems, targanta Therapeutics, Transmolecular Inc, Transport Pharmaceuticals, Vertex Pharmaceuticals, and Ziopharm. Last year was a banner year for venture capital fi...

Targanta Therapeutics Announces Pricing of its Initial Public Offering

.... All of the shares are being offered by Targanta. targanta has granted to the underwriters a 30-day option to...ies laws of any such state or jurisdiction. About targanta Therapeutics targanta Therapeutics Corporation is a biopharmaceutical co...

Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting

...eting CAMBRIDGE, Mass., Sept. 12 /PRNewswire/ -- targanta Therapeutics Corporation today announced that 23 p.... Thomas Parr, Ph.D., Chief Scientific Officer of targanta Therapeutics commented on the meeting: "We are ver...d of the body of data being presented on behalf of targanta at ICAAC this year-a true testament, we believe, t...
Other Tags
(Date:7/9/2014)... YORK (July 8, 2014) Researchers from Montefiore ... of Medicine of Yeshiva University will present new ... held July 12 July 17 in Copenhagen, Denmark. ... that could prompt transition from cognitive normality to mild ... the Einstein Aging Study , established in 1980 ...
(Date:7/9/2014)... for more than watching World Cup highlights, Brian Williams ... landing in unfortunate positions on railings. A University of ... Online Journal shows that YouTube also allows researchers, ... public on topics of skin cancer and prevention. , ... the future of how we communicate around the world," ...
(Date:7/9/2014)... Diseases (NIAID), part of the National Institutes of ... CRS3123, an investigational oral antibiotic intended to treat ... infection. CRS3123 (previously known as REP3123) is a ... sparing normal intestinal bacteria. , The Phase I ... and women ages 18 to 45 in a ...
(Date:7/9/2014)... 2014) A retrospective study conducted by researchers at ... that among adults with intellectual and developmental disabilities, the ... years receiving dental care increased. The findings, published in ... , may help improve interventions designed to address the ... The researchers reviewed the dental records of 107 patients ...
(Date:7/9/2014)... with kidney and heart disease have raised concerns about ... However, in the first study to look closely at ... at the University of Pennsylvania report that older kidney ... and cardiovascular health as very healthy older people who ... ever increasing organ transplant waitlists, the authors of the ...
Breaking Medicine News(10 mins):Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2
(Date:7/9/2014)... one of the amphibians with the highest distribution in ... of water where it comes into contact with the ... carried out by the Spaniard Germn Orizaola from the ... these frogs have developed a defensive response to the ... bodies if they co-exist with the crayfish. , Numerous ...
(Date:7/9/2014)... function and increase the survival rate of naturally ... School of Pharmaceutical Sciences, Southwest University, China performed ... administered with low dose of levothyroxine for 3 ... exhibited an obvious improvement in cognitive and an ... The underlying mechanism was demonstrated that levothyroxine treatment ...
(Date:7/9/2014)... vitamin D in their blood are more likely to survive ... highest levels of vitamin D have half the risk of ... reveal. , The study is the first to correlate total ... their diagnosis which includes that produced after exposure to ... long term survival prospects. , The University of Edinburgh ...
Breaking Biology News(10 mins):Frogs have developed rapid defences against the red swamp crayfish 2Frogs have developed rapid defences against the red swamp crayfish 3
Other Contents